ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Adverse effects"

  • 2018 American Transplant Congress

    Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study

    J. Fung,1 F. Saliba,1 H. Schlitt,1 G. Junge,2 K. McCague,3 D. Patel,3 M. Charlton.1

    1H2304 Study Group, Chicago; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…
  • 2018 American Transplant Congress

    Preventing Recurrence of Incisional Hernia after Liver Transplantation

    J. Butler, D. O'Brien, J. Kays, C. Kubal, B. Ekser, J. Fridell, R. Mangus, J. Powelson.

    Transplant Surgery, Indiana University, Indianapolis, IN.

    Background: Incisional hernia is a well-known complication of orthotopic liver transplantation (OLT). Although factors that affect incidence of hernia after OLT have been described, recurrence…
  • 2018 American Transplant Congress

    Post-Hoc Analysis of Everolimus Trough Levels around the Onset of Related Adverse Events and Treatment Discontinuation in De Novo Kidney Transplant Recipients from the US92 Study

    F. Shihab,1 Y. Qazi,1 V. Peddi,1 D. Shaffer,1 K. McCague,2 D. Patel,2 S. Mulgaonkar.1

    1US92 Study Group, Salt Lake City; 2Novartis Pharmaceutical Corporation, East Hanover.

    Purpose: Around 30%-50% of kidney transplant recipients (KTR) on sirolimus discontinue treatment due to drug-related adverse events (AE) and ~23% on everolimus (EVR) discontinue treatment…
  • 2018 American Transplant Congress

    Closing Pandora's Box: An Evidence Based Approach to Opioid-Tolerant Patients Following Transplantation. The Case for IV Methadone

    A. Aljassem, L. Hall, S. Cohn, D. Bedi, M. Alsibae, K. Putchakayala, S. Tasleem, D. Samarapungavan, C. Carpenter, A. Koffron.

    Department of Surgery, Beaumont Health, Royal Oak, MI.

    The purpose of this study is to explore the use of parenteral methadone in opioid-tolerant patients who are status-post transplantation. As an alternative to traditional…
  • 2018 American Transplant Congress

    Renal-Sparing Protocol May Be Harmful If Performed Early Post-Heart Transplant

    J. Patel, M. Johl, E. Kransdorf, M. Kittleson, S. Dimbil, R. Levine, D. Chang, L. Czer, J. Kobashigawa.

    Cedars Sinai Medical Center, Los Angeles, CA.

    Purpose: Calcineurin inhibitors (CNIs) are associated with nephrotoxicity. Renal sparing protocol (RSP) with CNI free regimen using mycophenolate and a proliferation signal inhibitor may improve…
  • 2018 American Transplant Congress

    Patient Experience after Kidney Transplant: Factors That Lessen the Burden of Treatment after Kidney Transplant

    E. Lorenz,1 J. Egginton,1 M. Stegall,1 R. Heilman,2 S. Nair,2 M. Mai,3 D. Eton.1

    1Mayo Clinic, Rochester; 2Mayo Clinic, Scottsdale; 3Mayo Clinic, Jacksonville.

    Background: Patients face a daunting regimen of medications, health monitoring and medical appointments following kidney transplant. This workload of healthcare and its impact on patient…
  • 2018 American Transplant Congress

    Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation

    A. Dao, S. Tremblay, A. Shields, A. Loethen, B. Abu Jawdeh, T. Diwan, A. Govil, E. Woodle, R. Alloway.

    UCincinnati, Cincinnati.

    Mycophenolate mofetil (MMF) is generally administered as a fixed dose. Studies have shown a relationship between MPA exposure (MPAAUC) but no data evaluates this relationship…
  • 2018 American Transplant Congress

    Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant

    Y. Lu,1 J. Lyons,2 S. Tischer,2 K. Woodside,3 J. Park.2

    1Transplant Nephrology, University of Michigan, Ann Arbor, MI; 2Transplant Pharmacy, University of Michigan, Ann Arbor, MI; 3Transplant Surgery, University of Michigan, Ann Arbor, MI.

    Background: For patients with end stage renal disease (ESRD) due to primary focal segmental glomerulosclerosis (FSGS), there is a significantly increased risk for disease recurrence…
  • 2018 American Transplant Congress

    The Infusion with a Difference: Patient Experiences with Belatacept

    H. Murad, D. Malhotra, E. Cohen, W. Asch.

    Yale University, New Haven, CT.

    Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…
  • 2018 American Transplant Congress

    Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients

    M. Benincasa,1 V. Colomy,1 N. Sifontis,1 S. Rao,2 K. Lau,3 S. Karhadkar,3 A. Di Carlo,3 A. Diamond.4

    1Pharmacy Practice, Temple School of Pharmacy, Philadelphia, PA; 2Medicine, Temple School of Medicine, Philadelphia, PA; 3Surgery, Temple School of Medicine, Philadelphia, PA; 4Pharmacy, Temple University Hospital, Philadelphia, PA.

    Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 18
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences